...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current oncology reports. >Targeting the Androgen Receptor in Breast Cancer
【24h】

Targeting the Androgen Receptor in Breast Cancer

机译：靶向乳腺癌中的雄激素受体

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The androgen receptor (AR) is expressed in the majority of breast cancer and across the three main breast cancer subtypes. Historically, the oncogenic role of AR has best been described in molecular apocrine breast cancers, an estrogen receptor (ER)-/AR+ subtype which has a steroid response signature similar to that in the ER-positive breast cancer. The signalling effect of AR is likely to be different across breast cancer subtypes, and particularly important is its interaction with ER signalling. Despite the high frequency of AR expression in breast cancer, it is still not a standard clinical practice to use AR antagonists as therapy. Older trials of AR-directed therapies in breast cancer have had generally been disappointing. More recently, more potent, next-generation, AR-directed therapies have been developed in the context of prostate cancer. Here, we will review the emerging literature dissecting the role of AR signalling in a context-dependent manner in breast cancer and the renewed interest and wave of clinical trials targeting the AR in breast cancer.
机译：雄激素受体（AR）在大多数乳腺癌和三个主要乳腺癌亚型中表达。从历史上看，AR的致癌作用最佳地描述于分子口腔乳腺癌，雌激素受体（ER） - / AR +亚型，其具有与ER阳性乳腺癌中的类固醇反应特征类似。 AR的信号效应可能在乳腺癌亚型中不同，并且特别重要的是其与ER信号的相互作用。尽管乳腺癌中AR表达的高频率，但仍然不是使用AR拮抗剂作为治疗的标准临床实践。乳腺癌中Ar导向疗法的旧试验一般都令人失望。最近，在前列腺癌的背景下已经开发了更有效的，下一代的AR导向的疗法。在这里，我们将审查以乳腺癌中依赖于上下文的方式解剖AR信号传导的发挥作用以及靶向乳腺癌中AR的临床试验的新兴的兴趣和波浪。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号